Speaker: Mel Reichman, Ph.D., Director, LIMR Chemical Genomics Center (LCGC), Senior Investigator, Lankenau Institute for Medical Research (LIMR)
Date: Tuesday, December 13, 2016
Time: 4:00 p.m. EDT
Login: Register Now
Speaker: Mary Luper, ALS Research Ambassador
The November 14th ALS Association/Northeast ALS Consortium PALS webinar will feature Mary Luper, a PALS who will be sharing her experiences with ALS advocacy. Mary has learned a lot on the topic of advocacy over the past two years and hopes to share this knowledge with other PALS and CALS interested in raising disease awareness. She will be joined by Dr. Richard Bedlack from the Duke ALS Clinic, who will be available to answer questions during the live Q&A.
Date: Monday, November 14, 2016
Time: 4:00 p.m. EDT
Login: Register Now
Expanding mechanisms and therapeutic targets for ALS
Speaker: Aaron Gitler, Ph.D., Associate Professor of Genetics, Stanford University
Watch this webinar
Genomic Translation for ALS Care (GTAC study): Envisioning the Precision Medicine Future for ALS
Speaker: Matthew Harms, M.D., Director of GTAC and Assistant Professor of Neurology at Columbia University Medical Center
View summary of this webinar
Watch this webinar
Speaker: Mervyn J. Monteiro, Ph.D., Professor, University of Maryland School of Medicine
View summary of this webinar
Watch this webinar
Speakers: John Landers, Ph.D., University of Massachusetts Medical Center and Dr. Leonard van den Berg, Director Netherlands ALS Center, Utrecht, Netherlands
View summary of this webinar
Watch this webinar
Speaker: James Shorter, M.A., Ph.D., Associate Professor, Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania
View summary of this webinar
Watch this webinar
Speaker: Terry Heiman-Patterson, M.D., Professor and Vice Chair of the Department of Neurology at Drexel University College of Medicine
View summary of this webinar
Watch this webinar
Speaker: Bob Koppes, MSc, M.B.A., Accenture Management Consulting
View summary of this webinar
Watch this webinar
Speakers:
Benjamin Wolozin, M.D., Ph.D., Professor of Pharmacology and Neurology, Boston University School of Medicine, Co-founder Aquinnah Pharmaceuticals
Glenn Larsen, Ph.D., CEO, Aquinnah Pharmaceuticals Inc
View summary of this webinar
Watch this webinar
Speaker: Clotilde Lagier-Tourenne, M.D., Ph.D.
View summary of this webinar
Speaker: David L. Ennist, PhD, MBA
Watch this webinar
View summary of this webinar
Speaker: Dr. Robert Bowser, PhD, President, Iron Horse Diagnostics, Inc., Dr. Andreas Jeromin, PhD, Chief Scientific Officer, Iron Horse Diagnostics, Inc.
Watch this webinar
View summary of this webinar
Speaker: Dr. Phillip Wong, Professor of Pathology at Johns Hopkins University School of Medicine
View summary of this webinar
Speaker: Bjorn Oskarsson, M.D., University of California. Davis
View summary of this webinar
Speaker: Dr. Lucie Bruijn, Chief Scientist, The ALS Association
View summary of this webinar
Speaker: Dr. Michael Benatar, University of Miami Health System
View summary of this webinar
Speaker: Steven Finkbeiner, M.D., Ph.D., Professor, Departments of Neurology and Physiology, University of California, San Francisco
View recording of this webinar
Speaker: Don W. Cleveland, Head, Laboratory for Cell Biology, Ludwig Institute for Cancer Research; Distinguished Professor and Chair, Dept. of Cellular and Molecular Medicine, Univ. of California, San Diego
View summary and recording of this webinar
Speaker: Nazem Atassi, MD, MMSc, Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital
View summary and recording of this webinar
Speaker: Clive Svendsen, Ph. D., Director, The Board of Governors Regenerative Medicine Institute at Cedars Sinai Medical Center
View summary and recording of this webinar
Speaker: Hemali Phatnani, Ph.D., The New York Genome Center
View summary and recording of this webinar
Speaker: Lucie Bruihn, MBA, PhD
View summary and recording of this webinar
Speaker: John Landers, Ph.D., Professor, University of Massachusetts Medical School
>View summary and recording of this webinar
Speaker: Lucie Bruijn, M.B.A., Ph.D., Chief Scientist, The ALS Association
View summary and recording of this webinar
Speaker: Michael Benatar, M.D., Ph.D., Associate Professor of Neurology at the University of Miami
View summary and recording of this webinar
Speaker: Lyle W. Ostrow, M.D., Ph.D., Johns Hopkins School of Medicine
View summary and recording of this webinar
Speaker: Joan Coates, D.V.M.
View summary and recording of this webinar
Speaker: Ed Kasarskis, M.D., ALSA Certified Center Director
View summary and recording of this webinar
Speaker: Lucie Bruijn, PhD, Chief Scientist, The ALS Association
View summary and recording of this webinar
Speaker: Heather D. Durham, PhD, Professor, Department of Neurology and Neurosurgery and Montreal Neurological Institute, McGill University
View summary of this webinar
Speaker: Paul Taylor, M.D., Ph.D., St. Jude Children's Research Hospital
View summary and recording of this webinar
Speaker: Brian D. McCabe, Ph.D. Assistant Professor, Columbia University, New York, N.Y.
View summary and recording of this webinar
Speaker: Ammar Al-Chalabi, M.D.
Professor of Neurology and Complex Disease Genetics, and Director of King’s MND Care and Research Centre at King’s College in London
View summary and recording of this webinar
Speaker: Rita Sattler, Ph.D.
Assistant Professor, Dept. of Neurology, Brain Science Institute
Principal Scientist, NeuroTranslational Drug Discovery Program
Johns Hopkins School of Medicine
View recording of this webinar
Speaker: Dr. Lucie Bruijn
View summary and recording of this webinar
Speaker: Steven Burden, Ph.D., NYU LangoneMedical Center
View summary and recording of this webinar
Speaker: Dr. Kirsten Gruis
View summary and recording of this webinar
Speaker: Dr. Jonathan Glass
View summary and recording of this webinar
Speaker: Dr. James Berry
During a recent ALS Association research webinar, James Berry, M.D., M.P.H., discussed how telemedicine may soon be used to provide care to those with ALS without leaving their home.
View summary and recording of this webinar
Speaker: Lucie Bruijn, Ph.D., The ALS Association
View summary of this webinar
Speaker: Andreas Jeromin, Ph.D.
View summary of this webinar
Speaker: Howard Weiner, MD, Brigham and Women's Hospital
View summary of this webinar
Speaker: Janice Robertson, Ph.D.
View summary of this webinar
Speaker: Michael Benatar, M.D.
View Summary of this webinar
Speaker: Dr. Chris Shaw, 2012 Sheila Essey Award recipient
View recorded webinar
Speaker: Clive Svendsen, Ph.D., Director, Cedars-Sinai Regenerative Medicine Institute
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=1a0273b4d34964bc096e456be3eb48ad
Speaker: Professor Virginia Lee, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=82e2a67b0b5206872745098a40076f44
Leonard Petrucelli, Ph.D. Chair of Neuroscience
Mayo Clinic, Jacksonville, Florida
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=d46a2f36073ae80aa61a5a1615a7bc2f
Stephen Finkbeiner, M.D., Ph.D. from the Gladstone Institute, UCSD
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=47c11c81755b572cc30a1090abe799c8
Presented by Catherine Lomen-Hoerth, MD, neurologist and director of the ALS Center at UCSF Medical Center in San Francisco, California.
View summary of this webinar
Presented by: Cathleen Lutz, PhD, Jackson Laboratories
In a recent webinar The ALS Association sponsored, Cathleen Lutz, Ph.D., Associate Director of the Genetic Resource Science Repository at Jackson Laboratories, spoke about the Lab’s work to develop, maintain and distribute ALS mice.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=f572c85acfe3c0b24ee22bfd73f7a6ab
A newly-discovered mutation is the most common known genetic cause of familial ALS and also accounts for some sporadic ALS cases. Researchers now have new clues about ALS and familial frontotemporal dementia (FTD). Hear Rosa Rademakers, PhD, and Bryan Traynor, MD discuss the implications of the new research.
Rosa Rademakers is with the Department of Neuroscience at the Mayo Clinic in Jacksonville, Florida. Her research is centered around the molecular genetic analyses of neurodegenerative diseases with a main focus on frontotemporal dementia (FTD) and ALS.
Bryan Traynor is Chief of the Neuromuscular Diseases Research Group in the Laboratory of Neurogenetics at the National Institutes of Health (NIA) and an adjunct faculty member of the Neurology Department, Johns Hopkins.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=d5cf52113c46da44164e7cd9571dc23e
Professor of Neurology, Northwestern University.
Dr. Siddique was the senior researcher for the new gene linked to familial ALS involved in the processing of accumulated proteins, Ubiquillin-2. He has dedicated most of his career to neurological disorders such as ALS. Dr. Siddique will be speaking of the discovery of the Ubiquillin-2 and its impact on the future of ALS research.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=50c171f2719a0110bc12a1f2138b0ec1
Dr. Merit Cudkowicz
Professor of Neurology, Harvard Medical School
Dr. Cudkowicz chairs the Northeast ALS Consortium (NEALS) where they are dedicated to developing and implementing clinical trials and other research studies focused on the understanding of ALS and improving the care of those living with the disease.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=4b167047796403a0144aeafaeec1297b
Nicholas Maragakis, M.D.
Johns Hopkins School of Medicine, Baltimore, MD
Despite decades of discussion over the potential benefit or harm of exercise in ALS, no study has compared these two forms of exercise, resistance and endurance, with the current standards of ALS care—stretching and range of motion exercise. The ALS Association is funding Dr’s Nicholas Maragakis and Merit Cudkowicz to address these questions in a randomized, controlled study with the long term goal of establishing a larger efficacy study and eventually a consensus statement on the potential benefits (or detriments) of exercise in this neurodegenerative disease.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=5785dfba8ecfb75a70949b6f876a9691
Ammar Al-Chalabi, MD
MRC Center for Neurodegenerative research
Insititute of Psychiatry
London, UK
Keeping up with the rapidly changing field of ALS genetics is difficult. New genes thought to cause ALS with varying levels of scientific support are reported almost every month, and even for those that are widely regarded as being true ALS genes, the exact variations within them and how they relate to disease may be difficult to understand. One way to overcome this problem is by collecting all the scientific reports and unpublished genetic information in one place, combining information about the clinical picture with genetics to see if new patterns emerge. The ALS Online Database (ALSoD) found at http://alsod.iop.kcl.ac.uk currently records information on 74 possible ALS genes with tools for analysis and summaries of the relationships between those genes and patterns of ALS.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=210f88405fbb6e88f7abbe7227353ba2
Summary: Online Database of ALS Genes
Keeping Up with Genetic Discoveries in ALS
Tom Maniatis, Ph.D.
Columbia Medical School, New York, NY
Identification of mutations in TDP43 linked to familial ALS has opened up new avenues for research. Using novel technologies, Dr. Maniatis’s laboratory is attempting to understand how TDP43 causes ALS, enabling the identification of new approaches to treat ALS.
Dr. Seward Rutkove
Beth Israel Deaconess Medical Center
Dr. Seward Rutkove’s biomarker, a method called electrical impedance myography (EIM), sensitively measures the flow of a tiny, painless, electrical current through muscle tissue. As the disease progresses, ALS patients’ muscles atrophy, and the more their muscles weaken and shrink, the greater the change detected as the current moves through the muscle. By comparing the size and speed of the electrical current as it passes through healthy and diseased tissue, EIM can accurately measure the progression of the disease.
View archived webinar at https://alsa.webex.com/alsa/ldr.php?AT=pb&SP=MC&rID=62567427&rKey=4e32152d4abb5a59
Bryan Traynor, M.D.
National Institute of Aging, Bethesda, MD
Exome sequencing is a new technique, which allows researchers to rapidly sequence the 1% of the human genome that codes proteins; this is where 85% of the mutations causing familial ALS lies. Using this technology, Dr. Traynor identified a new gene, valosin-containing protein (VCP), which is linked to familial ALS.
View summary of this webinar at http://www.alsa.org/news/archive/whole-exome-sequencing.html
Ashkan Javaherian, Ph.D.
iPierian, San Francisco, CA
Adult skin cells can be manipulated to generate induced pluripotent stem cells to produce motor neurons and astrocytes, cells at risk in ALS. The ALS Association has awarded a one-year grant to iPierian to support the identification of a “cellular phenotype,” which represents differences in motor neurons or astroglial cells derived from ALS patients, versus healthy controls. This phenotype would be the basis for drug screening to identify potential disease-modifying drug candidates for ALS.